RCAG
BHVN

Rehmann Capital Advisory Group’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Rehmann Capital Advisory Group’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-17
Closed -$638 – 2274
2018
Q3 		$638 Sell
17
-27
-61% -$993 ﹤0.01% 2049
2018
Q2 		$1.74K Buy
44
+27
+159% +$857 ﹤0.01% 1840
2018
Q1 		$0 Buy
+17
New +$508 ﹤0.01% 2094

Other funds holding BHVN

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Rehmann Capital Advisory Group's BHVN Position: Q4 2018 in Review

Rehmann Capital Advisory Group sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2018, closing a stake of 17 shares — an estimated $638 sold.

Rehmann Capital Advisory Group first reported a position in BHVN in Q1 2018 and held it in 3 quarters. The position peaked at $1.74K in Q2 2018. 131 funds tracked by Wall St. Rank hold BHVN as of Q4 2018.

  • Rehmann Capital Advisory Group reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2018 after selling out during the quarter.
  • Rehmann Capital Advisory Group sold 17 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2018, an estimated $638.
  • Rehmann Capital Advisory Group first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2018 and held it in 3 quarters.
  • Rehmann Capital Advisory Group's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $1.74K in Q2 2018.
  • 131 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2018.

Based on Rehmann Capital Advisory Group's 13F filing for Q4 2018, filed 12 Feb 2019.